StockData
Xencor Inc logo

Xencor Inc (XNCR) stock

XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30194% above fair value
$34.39−0.11 (-0.32%)

Close on Nov 18, 2026Market cap $2.56BP/E –Yield –

Xencor r&d expenses

Research and development expenses are spending on new products and technology.

Xencor's R&D Expenses for the twelve months ending Jun 30, 2026 was $255.77M, up 11.4% year over year. For fiscal 2025 it was $239.43M, up 5.2% from the year before. Over ten years it grew 21.5% a year on average. The highest annual figure on record is $253.60M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$239.43M+5.2%
FY2024Dec 31, 2024$227.69M-10.2%
FY2023Dec 31, 2023$253.60M+27.1%
FY2022Dec 31, 2022$199.56M+3.7%
FY2021Dec 31, 2021$192.51M+13.4%
FY2020Dec 31, 2020$169.80M+43.2%
FY2019Dec 31, 2019$118.59M+21.6%
FY2018Dec 31, 2018$97.50M+35.8%
FY2017Dec 31, 2017$71.77M+38.4%
FY2016Dec 31, 2016$51.87M+51.9%
FY2015Dec 31, 2015$34.14M+84.4%
FY2014Dec 31, 2014$18.52M+8.9%
FY2013Dec 31, 2013$17.00M+34.2%
FY2012Dec 31, 2012$12.67M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$71.91M+16.6%
Q1 FY2026Mar 31, 2026$64.67M+10.4%
Q4 FY2025Dec 31, 2025$64.82M+27.0%
Q3 FY2025Sep 30, 2025$54.37M-6.6%
Q2 FY2025Jun 30, 2025$61.67M+0.2%
Q1 FY2025Mar 31, 2025$58.58M+3.0%
Q4 FY2024Dec 31, 2024$51.06M-19.0%
Q3 FY2024Sep 30, 2024$58.23M-10.3%
Q2 FY2024Jun 30, 2024$61.53M+2.4%
Q1 FY2024Mar 31, 2024$56.87M-13.2%
Q4 FY2023Dec 31, 2023$63.05M+22.5%
Q3 FY2023Sep 30, 2023$64.94M+21.9%
Q2 FY2023Jun 30, 2023$60.06M+27.6%
Q1 FY2023Mar 31, 2023$65.55M+37.3%
Q4 FY2022Dec 31, 2022$51.45M+0.9%
Q3 FY2022Sep 30, 2022$53.27M+5.3%
Q2 FY2022Jun 30, 2022$47.08M-4.9%
Q1 FY2022Mar 31, 2022$47.76M+15.3%
Q4 FY2021Dec 31, 2021$50.99M+6.3%
Q3 FY2021Sep 30, 2021$50.61M+13.9%
Q2 FY2021Jun 30, 2021$49.50M+13.9%
Q1 FY2021Mar 31, 2021$41.41M+22.0%
Q4 FY2020Dec 31, 2020$47.95M+75.4%
Q3 FY2020Sep 30, 2020$44.45M+49.3%
Q2 FY2020Jun 30, 2020$43.46M+30.5%
Q1 FY2020Mar 31, 2020$33.94M+20.4%
Q4 FY2019Dec 31, 2019$27.34M+0.8%
Q3 FY2019Sep 30, 2019$29.77M+42.1%
Q2 FY2019Jun 30, 2019$33.30M+42.7%
Q1 FY2019Mar 31, 2019$28.18M+8.0%
Q4 FY2018Dec 31, 2018$27.13M+33.0%
Q3 FY2018Sep 30, 2018$20.95M+8.0%
Q2 FY2018Jun 30, 2018$23.33M+37.9%
Q1 FY2018Mar 31, 2018$26.09M+73.4%
Q4 FY2017Dec 31, 2017$20.40M+52.7%
Q3 FY2017Sep 30, 2017$19.41M+37.9%
Q2 FY2017Jun 30, 2017$16.92M–
Q1 FY2017Mar 31, 2017$15.05M–
Q4 FY2016Dec 31, 2016$13.36M–
Q3 FY2016Sep 30, 2016$14.07M–

More Xencor figures

See a number that looks wrong?